AP Biosciences Inc (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
121.00
+1.50 (1.26%)
Sep 4, 2025, 1:54 PM CST
1.26%
Market Cap10.17B
Revenue (ttm)n/a
Net Income (ttm)-394.19M
Shares Out85.11M
EPS (ttm)-4.64
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume287,642
Average Volume966,782
Open122.50
Previous Close119.50
Day's Range119.50 - 124.50
52-Week Range36.30 - 178.00
Beta0.80
RSI53.68
Earnings DateAug 8, 2025

About AP Biosciences

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast ca... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.